Skip to main
MNKD
MNKD logo

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corp is positioned favorably due to its advancing orphan lung pipeline, which is expected to enhance long-term growth and diversification for the company. The management's strategic focus on education and marketing initiatives for Afrezza and Tyvaso DPI may further drive uptake, particularly as Tyvaso DPI gains market share in the pulmonary arterial hypertension (PAH) and pulmonary fibrosis (PF) sectors. Additionally, the potential approval of the Furoscix auto-injector could act as a substantial revenue driver, providing further stability and growth opportunities for MannKind's financial outlook.

Bears say

MannKind Corp's stock faces a negative outlook primarily due to the recent announcement of a competitive product by SQ Innovation, which has contributed to a significant 15.2% decline in share value, contrasting sharply with the broader biotech index performance. Additionally, the potential for successful challenges to the company's intellectual property and the emergence of well-capitalized competitors could adversely affect MannKind's market share and pricing power, particularly in the development of their products MNKD-102 and MNKD-201 for underserved diseases. Furthermore, setbacks from negative trial readouts, regulatory submission issues, or adverse decisions could hinder commercialization efforts and limit market potential, further compounding the company's financial risks.

MannKind (MNKD) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 6 analysts, MannKind (MNKD) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.